# M&A Acquisitions Report - 2026-01-11

Generated on: 2026-01-11 01:49:02
Total Acquisitions: 1

## Edwards Comments on JenaValve Acquisition

**Date:** 2026-01-11
**Link:** [Edwards Comments on JenaValve Acquisition](http://www.businesswire.com/news/home/20260109944511/en/Edwards-Comments-on-JenaValve-Acquisition/)

**Summary:** IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the companyâ€™s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of patients. Aortic regurgitation (AR) is a deadly, progressive disease. It is typically under-detected and under-referred and carries very high mortality if left untreated. As a company pioneering first-of-its-kind innovations for unaddressed structural heart patient groups, Edwards remains committed to le

**Contact Information:**
Media: Amy Meshulam,
media@edwards.com
Investors:

Media: Amy Meshulam,
media@edwards.com
Investors:
investor_relations@edwards.com


---

